Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
Lara Danziger-Isakov, MD-MPH |
A Multicenter Prospective Study of Human Adenovirus Infection and Disease in Pediatric Human Stem Cell Transplant Recipients |
National Institutes of Health (NIH)/Children's Hospital of Philadelphia |
HHSN272201600014C |
8/22/18-12/31/21 |
$66,479 |
Lara Danziger-Isakov, MD-MPH |
A Phase II Multi-Center, Prospective, Randomized, Double Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematpoietic Stem Cell and Organ Transplant Recipients |
National Institutes of Health (NIH)/Northwestern University Medical School |
HHSN272201600016C |
9/1/21-8/31/22 |
$179,125 |
Steven Black, MD |
CISA Clinical Vaccine Safety Evaluation - Contributing C |
Ctr for Disease Control and Prevention |
200-2012-53661 |
9/16/20-9/28/22 |
$211,625 |
David I Bernstein, MD |
Mouse and Guinea Pig Models for Cytomegalovirus and Herpes |
National Institutes of Health (NIH) |
HHSN27200003 |
11/1/21-10/31/22 |
$787,849 |
Tina L Cheng |
Child Health Research Career Development Award (K12) |
National Institutes of Health (NIH) |
K12HD028827 |
12/1/21-11/30/22 |
$459,000 |
Elizabeth Schlaudecker, MD |
CISA 02 Maternal Flublok |
Ctr for Disease Control and Prevention |
200-2012-53661-0010 |
9/15/20-9/14/22 |
$179,997 |
Mary Allen Staat, MD |
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity |
National Institutes of Health (NIH) |
U01AI144673 |
5/1/22-4/30/23 |
$4,442,677 |
Sing Sing Way, MD-PHD |
Progesterone induced immune modulation during pregnancy |
National Institutes of Health (NIH) |
R01AI145840 |
7/1/21-6/30/22 |
$756,664 |
Robert W Frenck, MD |
RTOP FY2020.A1B1C1D10123-Task A |
National Institutes of Health (NIH) |
HHSN272201300016I |
7/12/21-7/11/22 |
$211,415 |
John J Erickson, MD-PHD |
Maternal microchimerism transfers cellular immunity to offspring |
National Institutes of Health (NIH) |
F32AI145184 |
7/1/21-6/30/22 |
$79,842 |
Paul W Spearman, MD |
Role of Vpu, Tetherin, and Siglec 1 |
National Institutes of Health (NIH) |
R01AI150475 |
9/1/21-8/31/23 |
$408,407 |
Robert W Frenck, MD |
Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) |
National Institutes of Health (NIH) |
UM1AI148372 |
12/1/21-11/30/22 |
$2,708,294 |
Paul W Spearman, MD |
Leadership Group for the Infectious Diseases Clinical Research Consortium |
National Institutes of Health (NIH)/Emory University |
A601880 |
12/1/21-11/30/22 |
$62,337 |
Paul W Spearman, MD |
Viral and Cellular Determinants of HIV-1 Assembly - Resu |
National Institutes of Health (NIH) |
R01AI150486 |
2/1/22-1/31/23 |
$357,750 |
Koichi Araki DVM |
Translational Regulation of CD |
National Institutes of Health (NIH) |
7R01AI139675 |
8/1/21-7/31/22 |
$454,637 |
Mary Allen Staat, MD |
PREVAIL COVID-19 Supplemental |
Ctr for Disease Control and Prevention |
U01IP001059 |
5/1/20-8/31/20 |
$1,545,487 |
Paul W Spearman, MD |
Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes |
National Institutes of Health (NIH) |
R01DA051895 |
5/1/22-4/30/23 |
$495,301 |
Joseph Edward Qualls, PHD |
Lactate metabolism and host defense against Mycobacterium tuberulosis |
American Lung Association |
IA-696872 |
7/1/21-6/30/22 |
$75,000 |
Joseph Edward Qualls, PHD |
Preserving T cell / antigen presenting cell interactions via shared L-arginine |
National Institutes of Health (NIH) |
R21AI148612 |
9/1/21-8/31/22 |
$198,750 |
Mary Allen Staat, MD |
IMPRINT COVID-19 Supplement |
National Institutes of Health (NIH) |
3U01AI144673-02S1 |
5/1/22-4/30/23 |
$816,161 |
Mary Allen Staat, MD |
Overcoming COVID-19 Vaccine Effectiveness |
Ctr for Disease Control and Prevention/Children's Hospital Boston |
75D30120C07725 Subco |
4/9/20-5/4/22 |
$59,946 |
Sing Sing Way, MD-PHD |
Covid Progesterone Supplement |
National Institutes of Health (NIH) |
3R01AI145840-02S1 |
12/1/21-6/30/22 |
$538,121 |
Robert W Frenck, MD |
DMID 21-0002: Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in healthy adults |
National Institutes of Health (NIH) |
3UM1AI148372-02S1 |
12/1/21-11/30/22 |
$1,629,888 |
Elizabeth Schlaudecker, MD |
CISA Pediatric COVID |
Ctr for Disease Control and Prevention |
200-2012-53661 |
1/1/21-12/31/23 |
$697,191 |
Elizabeth Schlaudecker, MD |
CISA Adult COVID |
Ctr for Disease Control and Prevention |
200-2012-53661 |
12/1/20-11/20/22 |
$743,179 |
Elizabeth Schlaudecker, MD |
CISA Maternal COVID |
Ctr for Disease Control and Prevention |
200-2012-53661 |
12/1/20-11/30/23 |
$697,827 |
Monica Malone McNeal |
PATH Vaccine Solutions |
Bill & Melinda Gates Foundation/PATH Vaccine Solutions |
PATH_McNeal,M |
7/1/21-3/31/23 |
$893,090 |
Andrew Cox, MD-PHD |
Improving vaccine efficacy by circumventing NK cell-mediated immune suppression |
National Institutes of Health (NIH)/Cornell University |
215518-3 |
7/1/21-6/30/22 |
$119,880 |
Nina S Prasanphanich, MD-PHD |
Mechanisms of increased maternal susceptibility to E. coli and correlates of protection by pre-conceptual priming |
National Institutes of Health (NIH)/Cornell University |
215518-8 |
7/1/21-6/30/22 |
$119,880 |
Mary Allen Staat, MD |
PICLFU Study |
National Institutes of Health (NIH)/Children's Hospital Boston |
GENFD0002024871 |
9/18/20-8/31/24 |
$40,273 |
Mary Allen Staat, MD |
US Enhanced Surveillance Network |
Ctr for Disease Control and Prevention |
1 U01IP001155-01-00 |
9/1/21-8/31/22 |
$1,078,854 |
Paul W Spearman, MD |
Defining Antibody responses to influenza vaccines in infants and young children |
The John Hauck Foundation |
Hauck_Spearman |
9/15/21-9/14/22 |
$100,000 |
Mary Allen Staat, MD |
US Enhanced Surveillance Network |
Ctr for Disease Control and Prevention |
1 U01IP001155-01-00 |
9/1/21-8/31/22 |
$362,789 |
Monica Malone McNeal |
Environmental Enteric Dysfunction and Rotavirus vaccine responses in Zambian |
Bill & Melinda Gates Foundation/Centre for Infectious Disease Research i |
M148F1 INV-0317593 |
8/15/21-2/28/22 |
$20,000 |
Robert W Frenck, MD |
Blood Donation for Development |
Fondazione Toscana Life Sciences |
FondazioneToscana - |
11/19/21-11/18/24 |
$4,438 |
Mark Murphy, DO |
Optimizing Voriconazole Therapy Using Model-Informed Precision Dosing |
Thrasher Research Fund |
Thrasher_Murphy |
1/1/21-12/31/21 |
$5,412 |
Paul W Spearman, MD |
Nippert - COVID VLP |
L&L Nippert Charitable Foundation |
L and L Nippert Spea |
12/1/21-11/30/22 |
$75,000 |
Paul W Spearman, MD |
Vaccinology Training Program |
National Institutes of Health (NIH) |
T32AI165396 |
2/9/22-1/31/23 |
$154,113 |
Lara Danziger-Isakov, MD-MPH |
Clinical Trials in Organ Transplantation |
National Institutes of Health (NIH)/Duke University |
A03-5348/1U01AI16309 |
8/13/21-5/31/22 |
$68,717 |
Total Annual Grant Award Dollars |
$21,905,395 |